Enanta Pharmaceuticals (NASDAQ:ENTA) Receives Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Enanta Pharmaceuticals (NASDAQ:ENTA) in a research note published on Tuesday,Benzinga reports. HC Wainwright currently has a $18.00 price target on the biotechnology company’s stock.

ENTA has been the topic of a number of other reports. JMP Securities reaffirmed a “market outperform” rating and set a $21.00 price objective (down from $22.00) on shares of Enanta Pharmaceuticals in a research note on Tuesday, November 26th. Robert W. Baird reduced their price target on Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating on the stock in a report on Tuesday, November 26th. Two equities research analysts have rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Enanta Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $17.25.

Enanta Pharmaceuticals Stock Up 14.1 %

ENTA opened at $5.59 on Tuesday. The stock has a market cap of $119.23 million, a PE ratio of -1.02 and a beta of 0.54. Enanta Pharmaceuticals has a 52 week low of $4.71 and a 52 week high of $17.80. The business’s fifty day simple moving average is $5.87 and its 200 day simple moving average is $9.61.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its earnings results on Monday, February 10th. The biotechnology company reported ($1.05) EPS for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative return on equity of 73.02% and a negative net margin of 171.57%. As a group, equities analysts anticipate that Enanta Pharmaceuticals will post -5.05 earnings per share for the current year.

Insider Buying and Selling at Enanta Pharmaceuticals

In other Enanta Pharmaceuticals news, CEO Jay R. Luly sold 5,142 shares of the stock in a transaction on Friday, December 6th. The stock was sold at an average price of $8.06, for a total value of $41,444.52. Following the completion of the sale, the chief executive officer now owns 801,638 shares in the company, valued at approximately $6,461,202.28. This represents a 0.64 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 13.89% of the company’s stock.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. US Bancorp DE boosted its holdings in shares of Enanta Pharmaceuticals by 4,933.7% during the 3rd quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 4,243 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new position in shares of Enanta Pharmaceuticals in the 4th quarter valued at about $26,000. Intech Investment Management LLC bought a new position in shares of Enanta Pharmaceuticals in the 4th quarter valued at about $58,000. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Enanta Pharmaceuticals in the 3rd quarter valued at about $122,000. Finally, Quest Partners LLC lifted its holdings in shares of Enanta Pharmaceuticals by 65.0% in the 3rd quarter. Quest Partners LLC now owns 19,123 shares of the biotechnology company’s stock valued at $198,000 after acquiring an additional 7,535 shares during the last quarter. Hedge funds and other institutional investors own 94.99% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.